Ginkgo Bioworks is the main flat stage for cell programming, and Zymergen reported that Ginkgo has finished its recently declared securing of Zymergen. The procurement is supposed to essentially improve Ginkgo’s foundation by incorporating solid robotization and programming capacities as well as an abundance of involvement across different natural designing methodologies.
“Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome their world-class team to Ginkgo. We are excited to integrate Zymergen’s capabilities into our platform and explore new and expanded partnerships and opportunities for their diverse array of product concepts currently under development.”
Jason Kelly, CEO, and co-founder of Ginkgo Bioworks
Under the provisions of the consolidation arrangement that went into on July 24, 2022, Zymergen investors got, for each portion of Zymergen normal stock, 0.9179 portions of Ginkgo Class A typical stock. Zymergen offers will never again be exchanged on Nasdaq. Ginkgo Class A typical stock will keep on exchanging on NYSE under the ticker symbol DNA.
About Ginkgo Bioworks
Ginkgo is building a platform to enable consumers to program cells as easily as we can program computers. The company’s position enables the use of biotechnology in a range of markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo also supported a number of COVID-19 response efforts, including an integrated K-12 trial, vaccine development optimization, and treatment discovery.
Zymergen is a biotechnology company that designs and manufactures molecules, microorganisms, and substances for various end markets. Zymergen partners with nature to create better products, a better way, for a better world.